溃疡性结肠炎新疗法的选择和使用实用指南。

IF 2.6 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Current Opinion in Gastroenterology Pub Date : 2024-04-12 DOI:10.1097/mog.0000000000001023

Tara Nagaraj, John Shinn, Kara De Felice

引用次数: 0

摘要

一些新的生物制剂（mirizikizumab）和小分子药物（upadacitinib、ozanimod、etrasimod）已被批准用于治疗中重度溃疡性结肠炎。迄今为止，还没有头对头试验来指导这些新药的定位和使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A practical guide to selecting and using new ulcerative colitis therapies.

Several new biologics (mirizikizumab) and small molecules (upadacitinib, ozanimod, etrasimod) are approved for the treatment of moderate-to-severe ulcerative colitis. To date, there are no head-to-head trials to guide positioning and use of these newer agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Gastroenterology 医学-胃肠肝病学

CiteScore

5.30

自引率

0.00%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in Gastroenterology features hand-picked review articles from our team of expert editors. With twelve disciplines published across the year – including gastrointestinal infections, nutrition and inflammatory bowel disease – every issue also contains annotated references detailing the merits of the most important papers.